Marrone Bio Innovations Inc (MBII.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|52||2016||Independent Chairman of the Board|
|62||2017||President, Chief Financial Officer|
|59||2015||Chief Executive Officer, Director|
|69||2017||Executive Vice President, General Counsel, Secretary|
|44||2014||Vice President of Sales|
- BRIEF-Marrone Bio Innovations qtrly basic, diluted net loss per common share $0.27
- BRIEF-Marrone Bio Innovations receives EPA approval for novel biofungicide
- BRIEF-Marrone Bio signs exclusive agreement with Kenya Biologics
- BRIEF-Marrone Bio Innovations receives positive results from Brazil trials
- BRIEF-Marrone Bio Innovations reports Q2 loss per share $0.25